CD19

212개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved212 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

CGTLimited DatastaleKyverna TherapeuticsPhase 2

KYV-101 anti-CD19 CAR-T cell therapy (KYV-101 anti-CD19 CAR-T cell therapy)

Lupus Nephritis; Lupus Nephritis - WHO Class III · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 11Status Discontinued
CGTLimited DatastaleTakedaPhase 2

Anti-CD19 CAR T Cells Preparation (Anti-CD19 CAR T Cells Preparation)

Hematologic Malignancies · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 10Status Recruiting
CGTLimited DatastaleHebei Senlang Biotechnology Inc…Phase 1

Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells (Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells)

19 and 22+ B Cell Hematologic Tumors; 19 and 20+ B Cell Hematologic Tumors · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 8Status Recruiting
CGTLimited DatastaleCity of Hope Medical CenterPhase 1

CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem T-lymphocytes (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem T-lymphocytes)

Central Nervous System Lymphoma · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 6Status Recruiting
CGTLimited DatastaleCity of Hope Medical CenterPhase 2

CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes)

Recurrent Mantle Cell Lymphoma; Refractory Mantle Cell Lymphoma · EGFR

#EGFR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 6Status Recruiting
CGTLimited DatastaleiCell Gene TherapeuticsPhase 1

BCMA-CD19 cCAR T cells (BCMA-CD19 cCAR T cells)

Relapsed/Refractory, Systemic Lupus Erythematosus (SLE) · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 5Status Recruiting
CGTLimited DatastaleGuangdong Ruishun Biotech Co., …Phase 1

CD19-CAR-DNT cells (CD19-CAR-DNT cells)

B-cell Non-Hodgkin's Lymphoma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 5Status Active
CGTLimited DatastaleTakedaPhase 1

CD19-CAR-T2 Cells (CD19-CAR-T2 Cells)

Acute Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 5Status Active
CGTLimited DatastaleNanjing Legend Biotech Co.Phase 1

Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy (Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy)

Lymphoma, B-Cell · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 5Status Discontinued
CGTLimited DatastaleGuangdong Ruishun Biotech Co., …Phase 1

CD19-CAR-DNT cells (RJMty19, RJMty19 (CD19-CAR-DNT cells))

Systemic Lupus Erythematosus · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 5Status Recruiting
CGTLimited DatastaleThe Children's Hospital of Zhej…Phase 1

KN5601 (anti-CD19/BCMA CAR NK cells, anti-CD19/BCMA CAR NK cells (KN5601))

Autoimmune Diseases; Systemic Lupus Erthematosus · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 5Status Recruiting
CGTLimited DatastaleYake Biotechnology Ltd.Phase 1

Assigned Interventions CD19/BCMA CAR T-cells (Assigned Interventions CD19/BCMA CAR T-cells)

Systemic Lupus Erythematosus; Autoimmune Diseases · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 4Status Active
CGTLimited DatastaleShenzhen Genocury Biotech Co., …Preclinical

CD19/BCMA-targeted CAR-T lentiviral vector drug (CD19/BCMA-targeted CAR-T lentiviral vector drug)

Autoimmune Diseases · CD19

#CD19#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 4Status Recruiting
CGTLimited DatastaleCity of Hope Medical CenterPhase 1

CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes)

B Acute Lymphoblastic Leukemia; Recurrent Acute Lymphoblastic Leukemia · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 4Status Recruiting
CGTLimited DatastaleUniversity of PennsylvaniaPhase 1

RNA anti-CD19 CAR T cells (RNA anti-CD19 CAR T cells)

Hodgkin Lymphoma With no Available Curative Treatment Options Who Have a Limited Prognosis · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 4Status Discontinued
CGTLimited DatastaleThe First Affiliated Hospital o…Preclinical

Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis. (Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis.)

Autoimmune Diseases · CD19

#CD19#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 3Status Recruiting
CGTLimited DatastaleJuno Therapeutics, Inc., a Bris…Phase 2

Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes (Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes)

CD19-Positive Neoplastic Cells Present; Recurrent Adult Acute Lymphoblastic Leukemia · EGFR

#EGFR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 3Status Active
CGTLimited DatastaleFondazione Matilde Tettamanti M…Phase 2

CARCIK-CD19 (CARCIK-CD19)

Acute Lymphoblastic Leukemia, in Relapse · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 3Status Active
CGTLimited DatastaleUniversity of PennsylvaniaPhase 1

RNA CART19 cells (CD19 RNA redirected autologous T-cells, CD19 RNA redirected autologous T-cells (RNA CART19 cells))

Hodgkin Lymphoma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 3Status Discontinued
CGTLimited DatastaleKecellitics Biotech Company LtdPhase 2

CD19 and CD22 targeted CAR-T cells (CD19 and CD22 targeted CAR-T cells)

Lymphoma, B-Cell · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 3Status Active

3 / 11 pages

← PreviousNext →